Comments to FDA: Postmarketing Safety Reports for Human Drug and Biological Products Share page: Docket Number: FDA-2008-N-0334 Comments regarding a proposed rule on electronic submission requirements for postmarketing safety reports for human drug and biological products. Download Document Issues: OTC Medicines Related Posts Press Releases and Statements CHPA Applauds White House Executive Order Prioritizing Lower Drug Costs and Access to Self-Care Apr 17, 2025 Press Releases and Statements CHPA Responds to Section 232 Investigation on Pharmaceuticals Apr 15, 2025 Press Releases and Statements CHPA Commends Lawmakers for Urging FDA to Protect the Rx-OTC-Switch Pathway Apr 11, 2025